Heron Therapeutics HRTX Insider Ownership

NASDAQ HRTX

$0.34 -0.01 (-4.06%)

As of: Oct 21, 2026 · 11:41 AM EDT

Insider Holdings by Owner

39.46Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

21.45%

▲+0.091% pp QoQ

Shares Held by Insiders

40.83Mn

filed for Sep 2026

▲+0.43% QoQ

Shares Outstanding

190.34Mn

190,335,000 shares

Direct Holdings

2.03Mn

Indirect: 38.80Mn

Net Shares Traded (QoQ)

+173.13K

net buying in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the past year, HRTX insiders did not buy or sell the stock on the open market.

In transactions other than open-market trades, Heron Therapeutics insiders received 91.84K shares in stock awards, acquired 1.61Mn shares through option exercises and conversions and gave up 24.07K shares to cover taxes or exercise prices over the past 12 months.
According to Business Quant data, insiders at Heron Therapeutics reported 40.83Mn shares in total in their latest Form 4 filings, up 0.43% from 40.66Mn shares at the end of Q2 2026 and up 4.25% from 39.17Mn shares at the end of Q3 2025.
Direct holdings account for 2.03Mn shares (4.97%) of HRTX's insider total, and indirect holdings through trusts, partnerships and family members for 38.8Mn shares (95.03%).
Holdings in Heron Therapeutics stock are reported by 12 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
HRTX's three largest insider shareholders, per their latest Form 4 filings, are Rubric Capital Management LP (10% owner, 30.05Mn shares), Adam Morgan (Director, 8.88Mn shares) and Craig A. Collard (Chief Executive Officer, 856.49K shares).
The largest insider, Rubric Capital Management LP, holds 73.59% of HRTX's insider total.
Institutions owned 70.23% of HRTX shares as of Q2 2026; insiders' latest Form 4 filings account for about 21.45%, leaving roughly 8.32% with other investors, including the public.
Over the past 12 months, 11 insiders reported transactions in Heron Therapeutics stock in 43 Form 4 filings.
The insider holdings and trades above for Heron Therapeutics reflect Form 4 filings through August 10, 2026.

Form 4 Holdings

Insiders Holding HRTX

Insiders 18

Shares held 39.46Mn

Of outstanding 20.73%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Capital Management Lp Rubric	TenPercentOwner	0	30,046,828	30,046,828	76.1%	17 Oct, 2025
2	Adam Morgan	Director	123,737	6,986,744	7,110,481	18.0%	03 Feb, 2026
3	Craig A Collard	Chief Executive Officer	856,492	0	856,492	2.2%	03 Aug, 2026
4	Ira Duarte	Evp, Chief Financial Officer	281,899	0	281,899	0.7%	03 Aug, 2026
5	William P Forbes	Evp, Chief Development Officer	241,173	0	241,173	0.6%	03 Aug, 2026
6	Barry D Quart	Chief Executive Officer	177,989	0	177,989	0.5%	17 Jan, 2023
7	Mark Earl Hensley	Chief Operating Officer	170,901	0	170,901	0.4%	10 Aug, 2026
8	Susan Rodriguez	Director	87,180	0	87,180	0.2%	04 Feb, 2025
9	Lisa Peraza	Vp, Chief Accounting Officer	55,907	0	55,907	0.1%	16 Jan, 2024
10	Waage Christian	Director	53,960	0	53,960	0.1%	03 Feb, 2026
11	Craig A Johnson	Director	53,960	0	53,960	0.1%	03 Feb, 2026
12	Michael Kaseta	Director	53,960	0	53,960	0.1%	03 Feb, 2026
13	Thomas Cusack	Director	53,960	0	53,960	0.1%	03 Feb, 2026
14	Sharmila Dissanaike	Director	53,960	0	53,960	0.1%	03 Feb, 2026
15	Stephen Davis	Director	52,032	0	52,032	0.1%	20 Dec, 2022
16	John Poyhonen	President Cco	46,648	0	46,648	0.1%	17 Apr, 2023
17	David Leslie Szekeres	Evp, Chief Operating Officer	33,754	0	33,754	0.1%	17 Jul, 2023
18	Kimberly Manhard	Evp, Drug Development	28,330	0	28,330	0.1%	17 Apr, 2023

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

852 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
06 Aug, 2026	Mark Earl Hensley	Chief Operating Officer	Acquired M	31,250	—	—	179,789	Direct
06 Aug, 2026	Mark Earl Hensley	Chief Operating Officer	Disposed F	8,888	$0.50	$4.44K	170,901	Direct
06 Aug, 2026	Mark Earl Hensley	Chief Operating Officer	Disposed M	31,250	$0.00	$0	343,750	Direct
30 Jul, 2026	Craig A Collard	Chief Executive Officer	Acquired M	50,021	—	—	821,703	Direct
30 Jul, 2026	William P Forbes	Evp, Chief Development Officer	Acquired M	11,769	—	—	236,153	Direct
30 Jul, 2026	Ira Duarte	Evp, Chief Financial Officer	Acquired M	13,535	—	—	277,381	Direct
31 Jul, 2026	Mark Earl Hensley	Chief Operating Officer	Acquired M	11,769	—	—	148,539	Direct
30 Jul, 2026	William P Forbes	Evp, Chief Development Officer	Disposed F	3,348	$0.50	$1.67K	232,805	Direct
31 Jul, 2026	Mark Earl Hensley	Chief Operating Officer	Disposed M	11,769	$0.00	$0	164,776	Direct
31 Jul, 2026	Craig A Collard	Chief Executive Officer	Acquired M	34,789	—	—	856,492	Direct
30 Jul, 2026	Ira Duarte	Evp, Chief Financial Officer	Disposed F	3,850	$0.50	$1.93K	273,531	Direct
31 Jul, 2026	William P Forbes	Evp, Chief Development Officer	Acquired M	11,694	—	—	244,499	Direct
30 Jul, 2026	Craig A Collard	Chief Executive Officer	Disposed M	50,021	$0.00	$0	700,295	Direct
31 Jul, 2026	Ira Duarte	Evp, Chief Financial Officer	Acquired M	11,694	—	—	285,225	Direct
31 Jul, 2026	Craig A Collard	Chief Executive Officer	Disposed M	34,789	$0.00	$0	347,886	Direct
31 Jul, 2026	William P Forbes	Evp, Chief Development Officer	Disposed F	3,326	$0.50	$1.66K	241,173	Direct
31 Jul, 2026	Ira Duarte	Evp, Chief Financial Officer	Disposed F	3,326	$0.50	$1.66K	281,899	Direct
30 Jul, 2026	William P Forbes	Evp, Chief Development Officer	Disposed M	11,769	$0.00	$0	164,776	Direct
30 Jul, 2026	Ira Duarte	Evp, Chief Financial Officer	Disposed M	13,535	$0.00	$0	189,492	Direct
31 Jul, 2026	Ira Duarte	Evp, Chief Financial Officer	Disposed M	11,694	$0.00	$0	116,944	Direct

Showing 1 to 20 of 852 transactions